Al Ameen Journal of Medical Sciences (Oct 2022)
A comparative study of outcome of myrigngoplasty with and without use of autologous platelet rich fibrin
Abstract
Introduction: Chronic suppurative otitis media is one of the commonest causes of hearing loss. In myringoplasty the most widely used and accepted method is underlay graft of temporalis fascia. Platelet-rich fibrin is a second-generation platelet concentrate; It serves as a resorbable membrane that offers both mechanical and inflammatory protection to the tympanic membrane graft. It accelerates cell proliferation and matrix remodelling; it does not induce any undesirable tissue reactions. Objectives: To study the efficiency of use of autologous platelet rich fibrin in closure of tympanic membrane perforation during myringoplasty by preventing graft lateralization, graft site infection, promoting quicker healing and improving the overall outcome. Methods: This study included 50 patients presented to the Department of Otorhinolaryngology, Al Ameen Medical College, Vijayapura from November 2019 to December 2021 with chronic suppurative otitis media. 50% of patients underwent myringoplasty with autologous PRF and remaining 50% without PRF, they served as control. Routine follow-up at the 21 days, 1 month and 3 months after surgery. Postoperative PTA was done at 3 months. Results: The graft uptake rate was found to earlier in PRF group at 3 weeks and 1 month in comparison to controls, which was statistically significant (p< 0.05). Conclusion: PRF is a cheap and cost effective platelet concentrate with enriched growth factors. It accelerates the tympanic membrane closure, prevents graft migration, site infection and improves overall success rate in myringoplasty. It has no noticeable side effects.